Adding Adjuvant Lapatinib to Trastuzumab Not Effective for HER2+ Breast Cancer

Share this content:
Adjuvant treatment that includes lapatinib did not significantly improve disease-free survival compared with trastuzumab alone.
Adjuvant treatment that includes lapatinib did not significantly improve disease-free survival compared with trastuzumab alone.

Adjuvant treatment that included lapatinib did not significantly improve disease-free survival compared with trastuzumab alone and added toxicity in patients with early human epidermal growth factor receptor 2 (HER2)-positive breast cancer, a new study published online ahead of print in the Journal of Clinical Oncology has shown.1

Although previous research demonstrated that lapatinib plus trastuzumab improved outcomes for patients with HER2-positive metastatic breast cancer and increased the pathological complete response in patients, their efficacy in the adjuvant setting remained unclear.

“The main hypothesis of ALTTO was that hitting HER2 with 2 targeted therapies should be better than using only one; because toxicity of simultaneous dual HER2 blockade could be an issue, one strategy that was also tested was the sequential administration of trastuzumab and lapatinib,” wrote principal investigator Martine Piccart-Gebhart, MD, PhD, professor of oncology at the Université Libre de Bruxelles in Belgium.

Therefore, researchers designed the phase 3 Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization (ALTTO) trial to compare lapatinib plus trastuzumab with trastuzumab alone in patients with early HER2-positive disease.

For the study, researchers enrolled 8381 patients and randomly assigned them to receive 1 year of adjuvant therapy with trastuzumab; lapatinib; trastuzumab then lapatinib; or lapatinib plus trastuzumab.

Patients in the trastuzumab group received a loading dose of 4 mg/kg once and then 2 mg/kg weekly in addition to chemotherapy or a loading dose of 8 mg/kg once and then 6 mg/kg every 3 weeks when administered alone. 

Patients in the lapatinib arm received 750 mg/day of lapatinib during chemotherapy or 1500 mg/day when given alone. Participants in the sequential arm received 12 weekly doses of intravenous trastuzumab followed by a 6-week washout period, and then 34 weeks of lapatinib 1500 mg/day.

RELATED: MRI Phenotypes Could Predict Breast Cancer Stage, Lymph Node Status

Those in the combination arm received trastuzumab plus lapatinib 750 mg/day during chemotherapy, which was dose-escalated to 1000 mg/day after chemotherapy had been completed.

Page 1 of 2

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters